Doyle Mittie
Known title: Chief Medical OfficerCIK: 0001918845
Associated companies
Transaction History
| AVTX | ▲ Buy | Option Exercise | 679 | $5K | 8/28/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 679 | $14K | 8/28/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 1,000 | $13K | 8/17/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 1,000 | $20K | 8/17/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 679 | $5K | 8/10/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 679 | $14K | 8/10/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 1,000 | $13K | 7/27/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 1,000 | $20K | 7/27/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 2,875 | $36K | 6/30/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 1,779 | $14K | 6/30/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 4,654 | $93K | 6/30/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 1,450 | $12K | 6/23/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 1,450 | $26K | 6/23/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 1,084 | $14K | 6/10/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 679 | $5K | 5/28/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 679 | $11K | 5/28/2026 | View on chart |
| AVTX | ▲ Buy | Grant | 43,500 | $0 | 5/21/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,000 | $38K | 5/15/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 3,000 | $56K | 5/15/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 77,905 | $985K | 5/6/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 28,650 | $230K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 27,538 | $496K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 5,000 | $98K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 44,944 | $953K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 19,015 | $426K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 10,058 | $230K | 5/6/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 1,000 | $13K | 5/5/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 679 | $5K | 5/5/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 1,679 | $27K | 5/5/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,970 | $50K | 4/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 3,970 | $72K | 4/6/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 679 | $5K | 4/1/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 679 | $11K | 4/1/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 19,500 | $247K | 3/16/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 5,992 | $48K | 3/16/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 25,492 | $412K | 3/16/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 1,013 | $4K | 12/10/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program
Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.